Browse by Person

View wider browse menu Up a level
[feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Number of items: 1.

Proceedings Paper

Jones, RH, Carucci, M, Casbard, AC et al. (10 more authors) (2019) Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER -positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial. In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 31 May - 04 Jun 2019, Chicago, IL, USA. American Society of Clinical Oncology .

This list was generated on Sun Sep 13 06:26:10 2020 BST.